[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)
[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)

With Big Pharma In Retreat, Ackman And Novartis Try A New Blueprint For Drug Companies

By:Posted: Apr 22nd, 2014In: Opinions & Features

4.22.2014 | Forbes

By Steve Brozak

Yesterday in a move that returned attention to healthcare takeovers, Bill Ackman, CEO of the hedge fund Pershing Square Capital, announced a bold and unusual move by partnering with pharmaceutical company, Valeant Pharmaceuticals International, Inc. to acquire a major stake in another biotech.  In this case it is Allergan, Inc., the makers of the injectable wrinkle-remover BOTOX, and several ophthalmic treatments.

For the full article, please click here.

Recent Posts